Search Within

Malin Lisa Hultcrantz

  1. "Even Rustad"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (13)
  3. Review (2)
  4. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (30)
  2. Department of Medicine (30)
  3. Hematologic Malignancies, Division of (30)
  4. Myeloma (30)
  5. Sloan Kettering Institute Postdocs (30)
  6. Hematologic Malignancies Research (28)

More Groups

People
  1. Even Rustad (30)
  2. Carl Landgren (27)
  3. Venkata Yellapantula (22)
  4. Sham Mailankody (16)
  5. Ahmet Dogan (15)
  6. Francesco Maura (15)

More People

Years
  1. 2021 (5)
  2. 2020 (11)
  3. 2019 (9)
  4. 2018 (5)
Publications
  1. Blood (12)
  2. Blood Cancer Journal (3)
  3. JAMA Oncology (3)
  4. Journal of Molecular Diagnostics (2)
  5. Nature Communications (2)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (12)
  2. Nature Publishing Group (5)
  3. American Medical Association (3)
  4. Elsevier Science, Inc. (3)
  5. American Association for Cancer Research (2)
  6. American Society of Clinical Oncology (1)

More Publishers

Results (30)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
    Journal Article

    Maclachlan, K. H.; Rustad, E. H.; Derkach, A.; Zheng-Lin, B.; Yellapantula, V.; Diamond, B.; Hultcrantz, M.; Ziccheddu, B.; Boyle, E. M.; Blaney, P.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001
    Journal Article

    Maura, F.; Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V. D.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: Feasibility, challenges, and direct comparison with high-sensitivity flow cytometry
    Journal Article

    Ho, C.; Syed, M.; Roshal, M.; Petrova-Drus, K.; Moung, C.; Yao, J.; Quesada, A. E.; Benhamida, J.; Vanderbilt, C.; Liu, Y.; more...
    Journal of Molecular Diagnostics (2021)

    Fulltext@MSK | Save
  • Revealing the impact of structural variants in multiple myeloma
    Journal Article

    Rustad, E. H.; Yellapantula, V. D.; Glodzik, D.; Maclachlan, K. H.; Diamond, B.; Boyle, E. M.; Ashby, C.; Blaney, P.; Gundem, G.; Hultcrantz, M.; more...
    Blood Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Copy number signatures predict chromothripsis and poor clinical outcome in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The genomic complexity of multiple myeloma precursor disease can be predicted using copy number signatures on targeted sequencing and SNP array data
    Meeting Abstract

    Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; Landgren, O.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save